Skip to main content

ORLY STOCK WRITE UP


ORLY (O'REILLY AUTOMOTIVE PARTS)

  • P/E: 16.3
  • GAAP DILUTED YEAR-OVER-YEAR EPS GROWTH LAST QUARTER:
  • ASSETS-LIABILITIES: 2.06
  • SECTOR: RETAIL TRADE
  • DIVIDEND: none

ORLY is a chain of Auto Parts stores. The company's share price plunged almost 19% 7/5/17, after reporting a decline in its same-store sales numbers. A rapidly expanding company, ORLY has a disproportionate amount of debt on its balance sheet.
In the last quarter, O'Reilly increased sales by almost 3%, while operating income decreased by almost 4%. However, the company did post an increase in EPS on a year-over-year basis by virtue of decreased taxation. Autozone has only 1% of the amount of cash as it does long-term debt. The company also reports that it has roughly twice as much assets as it does liabilities, with the majority of these holdings in inventory and property. Cash decreased from 4Q '16 to 1Q '17, coinciding with the rise in inventory, and property.
O'Reilly trades at a 33% premium to its closest competitor, AZO. Both companies have fallen approximately 35% in share price since the beginning of the year. AZO posts higher revenues, while both companies have increased revenue over the past consecutive 4 years. ORLY's growth rate is nearly twice AZO's. ORLY missed both the expectations of Wall Street and itself in the last quarter.
Founded as a family business in 1957, O'Reilly came public in 1993, and several members of the O'Reilly family serve on the company board. The last major insider purchase was made by Daniel O'Reilly, the chairman, in August of 2016. Gregory Henslee is the company's CEO. He joined the company in 1984 as a store employee, and has been CEO since 2013. Henslee has declared that the specialist advice offered in O'Reilly stores trumps Amazon services, as people require assistance in selecting automotive parts.
The company is estimated to report in late July, and will look to reverse the trend of missing expectations with its sales figures, and revenue growth. While the company's sales have grown exponentially, so has its share price, and the expectations of Wall Street. The price-to-earnings multiple is still below the average S&P stock.

SOURCES:









Labels:

Comments

Post a Comment

Popular posts from this blog

ISRG STOCK WRITE UP

ISRG (INTUITIVE SURGICAL INC) P/E: 48 GAAP DILUTED YEAR-OVER-YEAR EPS GROWTH LAST QUARTER: $1.13 SECTOR: HEALTH TECHNOLOGY ASSETS-LIABILITIES: 7.05 DIVIDEND: none ISRG is the ticker for Intuitive Surgical Inc, a company endeavoring in the manufacture and distribution of robotic surgical devices. The company recently gained FDA approval for a lower-cost device. They have a clean balance sheet with a history of upside surprises against earnings expectations, and report again 7/20/17. Revenues increased nearly 14%, while EPS increased 32% compared to the Q1 '16 results. While liabilities decreased on a year-over-year basis, assets decreased by a larger margin. R&D spending increased 36%, and administrative costs rose 16%. Taxes were cut in half, although the revenues increased, due to modified accounting principles, and tax benefits for the employee share-based compensation.. The ratio of assets-liabilities decreased from 9.14 to 7.05, which is...
1 comment
Read more

AMGN STOCK WRITE UP

AMGN P/E: 16.1 GAAP EPS Y-O-Y GROWTH LAST QUARTER: $.22 SECTOR: HEALTH TECHNOLOGY ASSETS-LIABILITIES: 1.62 DIVIDEND: 2.54% Amgen is a leading biotech company with a solid financial foundation. It has managed to reduce its spending on research and development while increasing revenue through its sales of established drugs such as Enbrel, and Prolia. The company has several rapidly growing drugs that are newer to the market, with many drugs in the company's pipeline. In its last quarter, Amgen posted 7.7% revenue growth with 7.5% net income growth. The company spent less, however, in the most recent quarter when compared with the comparable quarter from the prior year, on research and development. The reduction in operating margin came from an increased interest expense in the quarter. Although the company spent less on research and development, its revenue did increase. Amgen is continuing to innovate despite reduced research and development b...
Post a Comment
Read more

PXD STOCK WRITE UP

 PXD (PIONEER NATURAL RESOURCES) P/E: N/A GAAP DILUTED Y-O-Y EPS GROWTH LAST QUARTER: $.67 SECTOR: ENERGY MINERALS ASSETS-LIABILITIES: 1.58 DIVIDEND: .04% Pioneer Natural Resources has recently made the jaw-dropping switch from negative EPS to positive with its last quarter. Situated in the largest oil-producing region in the US, the company is utilizing its good fortune to produce profits. The company has a good balance sheet, a wealth of resources, and a business model which has afforded it growth. This last quarter does not mark the first occasion on which Pioneer has posted a profit. In 2014, and 2012, Pioneer posted a positive EPS for the full year. While the 2016 oil and gas revenues have grown from 2015, the 2014 and 2012 levels were higher. The company's revenue from oil and gas is largely based on market prices. In order to mitigate the market volatility, Pioneer has made efforts to reduce their cost of production, according to their earnin...
1 comment
Read more